Aligos Therapeutics Inc (ALGS)
0.98
0.00 (0.00%)
USD |
NASDAQ |
Mar 28, 16:00
0.9899
+0.01
(+1.01%)
After-Hours: 20:00
Aligos Therapeutics Cash from Financing (TTM): 88.33M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 88.33M |
September 30, 2023 | 0.513M |
June 30, 2023 | 0.515M |
March 31, 2023 | 0.184M |
December 31, 2022 | 0.164M |
September 30, 2022 | 0.595M |
June 30, 2022 | 78.57M |
Date | Value |
---|---|
March 31, 2022 | 78.58M |
December 31, 2021 | 78.68M |
September 30, 2021 | 271.44M |
June 30, 2021 | 192.54M |
March 31, 2021 | 192.47M |
December 31, 2020 | 192.35M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.164M
Minimum
Dec 2022
271.44M
Maximum
Sep 2021
90.38M
Average
78.58M
Median
Mar 2022
Cash from Financing (TTM) Benchmarks
Allogene Therapeutics Inc | 95.70M |
CEL-SCI Corp | 8.678M |
AIM ImmunoTech Inc | 0.338M |
IGC Pharma Inc | 2.856M |
NovaBay Pharmaceuticals Inc | 4.971M |